A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters
A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters

Letters | How to ensure the coronavirus vaccine is distributed equitably worldwide

  • Because developing a vaccine is such an uphill battle, pharmaceutical companies deserve a patent
  • However, the vaccine could be sold at different prices to different countries based on their purchasing power to allow for more equitable access

Topic |   Coronavirus pandemic: All stories
A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters
A nurse holds a potential vaccine for Covid-19 developed by China’s Sinovac, at a hospital in Porto Alegre, Brazil, on August 8. Pharmaceutical firms’ ability to patent vaccines and other drugs offers an incentive to go ahead with research and trials despite the attendant financial, institutional and opportunity costs involved. Photo: Reuters
READ FULL ARTICLE